NCI invites abstracts for conference on the $50M Childhood Cancer Data Initiative

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

NCI is formulating a plan to develop an innovative childhood cancer initiative focused on data sharing. The plan would be initiated with a proposed increase to NCI’s budget of $50 million beginning in fiscal year 2020 and continuing, as proposed by the White House, for a total of 10 years.

“At NCI, we strongly believe that harnessing the power of data can be a driver of that progress, which is why the institute plans to use these proposed funds to create the Childhood Cancer Data Initiative,” Douglas R. Lowy, acting director at NCI, said in a statement.

“The aim of the CCDI is to establish more efficient ways to share and use childhood cancer data to help identify novel therapeutic targets and approaches, underpin new drug development, and enable new research pursuits to better understand the biology of childhood cancers.”

To shape the scientific direction of the CCDI, NCI is hosting a planning symposium July 29–31 in Washington, DC. The symposium will gather leaders and stakeholders from academic, government, industry, and advocacy communities to discuss scientific and clinical research data needs, opportunities for developing a connected data infrastructure, ways to provide meaningful datasets for clinical care and associated research progress, and policies around collecting and sharing data.

Deadline for submitting an abstract is June 15.

Consideration will be given for abstracts submitted up until June 30 if space is still available, NCI officials said.

YOU MAY BE INTERESTED IN

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
When it comes to fighting cancer today, collaboration is key. At a time when funding is uncertain, yet innovative breakthroughs are accelerating every day, it’s more important than ever for oncologists, scientists, academic researchers, and community physicians, to come together to share knowledge and gain insights about the forefront of cancer research.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login